Core Points - The Shanghai Composite Index is at 4017.68 points, above the six-month moving average, with a slight decline of 0.29% [1] - A total trading volume of A-shares reached 15648.48 billion yuan today [1] - 113 A-shares have surpassed the six-month moving average, with notable stocks showing significant deviation rates [1] Summary by Category Stock Performance - The top three stocks with the highest deviation rates from the six-month moving average are: - Electric Investment and Financing (9.07%) - Jie Rong Technology (7.54%) - Annie Shares (4.91%) [1] - Other stocks with smaller deviation rates that have just crossed the six-month line include: - Baoland, Zhongnong Lihua, and Subote [1] Trading Data - The trading performance of selected stocks includes: - Electric Investment and Financing: +9.94% with a turnover rate of 2.09% - Jie Rong Technology: +10.00% with a turnover rate of 8.20% - Annie Shares: +6.44% with a turnover rate of 18.47% [1] - Additional stocks with notable performance include: - Yahua Electronics: +6.29% - Zhonglu Shares: +7.08% - Jinlihua Electric: +4.81% [1]

Group 1 - The core viewpoint of the news is that Saiseng Pharmaceutical has shown significant stock performance with a year-to-date increase of 79.17%, despite a recent decline over the past 60 days [1] - As of November 12, Saiseng Pharmaceutical's stock price reached 12.56 CNY per share, with a total market capitalization of 6.05 billion CNY [1] - The company has experienced a net inflow of main funds amounting to 15.82 million CNY, indicating positive investor sentiment [1] Group 2 - Saiseng Pharmaceutical's main business revenue composition includes cardiovascular drugs (43.08%), immune system drugs (30.28%), and neurological system drugs (25.17%) [1] - For the period from January to September 2025, the company reported a revenue of 309 million CNY, a year-on-year decrease of 4.41%, while the net profit attributable to the parent company was 51.86 million CNY, reflecting a year-on-year increase of 152.81% [2] - The company has distributed a total of 413 million CNY in dividends since its A-share listing, with 52.02 million CNY distributed in the last three years [3]

张宁女士符合《公司法》《深圳证券交易所上市公司自律监管指引第2号— —创业板上市公司规范运作》及《公司章程》规定的有关职工代表董事的任职资 格。本次职工代表董事选举完成后，公司第五届董事会中兼任公司高级管理人员 以及由职工代表担任的董事人数总计未超过公司董事总人数的二分之一。 特此公告。 北京赛升药业股份有限公司 董 事 会 2025 年 11 月 11 日 证券代码：300485 证券简称：赛升药业 公告编号：2025-049 北京赛升药业股份有限公司 关于职工代表大会选举职工代表董事的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 北京赛升药业股份有限公司（以下简称"公司"）于2025年11月11日召开2025 年第二次临时股东大会，审议通过了《关于修订<公司章程>的议案》等议案。根 据《中华人民共和国公司法》《深圳证券交易所上市公司自律监管指引第2号— —创业板上市公司规范运作》《关于新<公司法>配套制度规则实施相关过渡期安 排》《上市公司章程指引》等相关法律法规、规范性文件及《公司章程》的规定， 公司于同日召开职工代表大会，经公司职工代表大会民主 ...

北京市康达律师事务所 关于北京赛升药业股份有限公司 2025 年第二次临时股东大会的法律意见书 康达股会字【2025】第 0465 号 致：北京赛升药业股份有限公司 根据《中华人民共和国公司法》（以下简称"《公司法》"）、《上市公司 股东会规则》（以下简称"《规则》"）、《北京赛升药业股份有限公司章程》 （以下简称"《公司章程》"）及北京赛升药业股份有限公司（以下简称"公司"） 与北京市康达律师事务所（以下简称"本所"）签订的《法律顾问协议》，本所 律师受聘出席公司 2025 年第二次临时股东大会（以下简称"本次会议"或"本 次股东大会"），并出具本法律意见书。 为出具本法律意见书，本所律师谨作如下声明： 北京市朝阳区建外大街丁 12 号英皇集团中心 8、9、11 层 8/9/11/F, Emperor Group Centre, No.12D, Jianwai Avenue, Chaoyang District, Beijing, 100022, P.R.China 电话/Tel.: 010-50867666 传真/Fax: 010-56916450 网址/Website: www.kangdalawyer ...

证券代码:300485 证券简称：赛升药业 公告编号：2025-048 北京赛升药业股份有限公司 2025 年第二次临时股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东大会无增加、变更议案的情形。 1、会议召集人：公司董事会 2、会议方式：本次会议采取现场投票和网络投票相结合的方式 3、会议召开时间： （1）现场会议召开时间为：2025 年 11 月 11 日下午 14:30 （2）网络投票时间：通过深圳证券交易所交易系统进行网络投票的具体时 间为 2025 年 11 月 11 日 9:15-9:25、9:30-11:30 和 13:00-15:00；通过互联网 投票系统投票的具体时间为：2025 年 11 月 11 日 9:15-15:00 任意时间。 4、会议地点：北京市北京经济技术开发区兴盛街 8 号 5、会议主持人：董事长马骉先生 2、本次股东大会不涉及变更前次股东大会决议的情形。 3、本次股东大会采取现场投票与网络投票相结合的表决方式。 一、会议召开和出席情况 会议召开情况： 6、本次会议的召集、召开符合《公 ...

Core Viewpoint - The company, Sai Sheng Pharmaceutical, is committed to steadily advancing its development planning based on industry trends, market environment changes, and its own actual situation [1] Group 1 - The company is responding to investor inquiries regarding its development strategy [1] - The company emphasizes the importance of adapting to industry development trends [1] - The company acknowledges the need to consider market environment changes in its planning [1]

Core Viewpoint - Recently, the company received a renewed Drug Production License from the Beijing Drug Administration, which is valid until November 4, 2030, ensuring the continuity of its production operations without significant impact on its performance [1] Group 1 - The renewal of the Drug Production License was prompted by the impending expiration of the original license [1] - The new license acquisition guarantees the company's normal production and business operations [1] - The company does not anticipate any major impact on its financial performance due to this renewal [1]

证券代码：300485 证券简称：赛升药业 公告编号：2025-047 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 北京赛升药业股份有限公司（以下简称"公司"）近日收到北京市药品监督 管理局换发的《药品生产许可证》，换发后的《药品生产许可证》的有效期至2030 年11月4日，相关主要信息如下： 一、《药品生产许可证》的主要信息 企业名称：北京赛升药业股份有限公司 许可证编号：京20150111 北京赛升药业股份有限公司 关于公司取得换发《药品生产许可证》的公告 社会信用代码：911100007002230889 分类码：AhCh 注册地址：北京市北京经济技术开发区兴盛街8号 法定代表人：马骉 资者理性投资，注意投资风险。 特此公告。 有效期至：2030年11月4日 生产地址和生产范围： 北京市北京经济技术开发区兴盛街8号：小容量注射剂、冻干粉针剂（含激 素类）*** 北京市北京经济技术开发区凉水河二街乙2号院：小容量注射剂、冻干粉针 剂（含激素类）*** 二、对公司的影响及风险提示 本次换发《药品生产许可证》是基于原生产许可证即将到期，新生产许可证 的取得 ...

Core Insights - The recombinant protein industry in China, despite its late start, has rapidly developed due to continuous support from national industrial policies, leading to significant breakthroughs in technology, production processes, and quality control [1][15] - The market for recombinant proteins is expected to grow steadily, driven by increased investment in innovative drug research, rising demand for precision medicine, and the expansion of downstream application scenarios [1][15] Industry Overview - Recombinant proteins are proteins obtained through genetic engineering and cell engineering, essential for the development and production of biopharmaceuticals, cell immunotherapy, and diagnostic reagents [4] - The industry has experienced three stages: the initial stage (1970-1990), rapid development (1990-2000), and transformation and upgrading (2000-present) [8][9] Market Growth - The market size of China's recombinant protein industry is projected to grow from 5.1 billion yuan in 2015 to 27 billion yuan in 2024, with a compound annual growth rate (CAGR) of 20.34% [1][15] - The global recombinant protein market is expected to increase from $7 billion in 2015 to $18.5 billion in 2024, with a CAGR of 11.4% [13][14] Policy Support - The Chinese government has implemented various policies to encourage technological innovation and market expansion in the biopharmaceutical sector, including funding support for research and expedited drug approval processes [9][10] Industry Chain - The upstream of the recombinant protein industry includes raw materials and equipment, while the midstream consists of recombinant protein products, and the downstream includes customers such as research institutions and pharmaceutical companies [10] Competitive Landscape - The recombinant protein market is characterized by a diverse and dynamic competitive landscape, with major multinational pharmaceutical companies like Pfizer, Roche, and Novartis leading the market, while numerous small and medium-sized enterprises focus on innovative technologies [16][17] Development Trends - The industry is moving towards high-end products, focusing on complex structures and high-value proteins, with an emphasis on product activity, purity, and consistency [18] - Intelligent technologies, including AI and machine learning, are expected to enhance research and production processes, improving efficiency and product quality [19][20] - Chinese recombinant protein companies are increasingly participating in global competition, aiming to meet international standards and establish a strong global presence [21]

Core Viewpoint - The company, Sai Sheng Pharmaceutical, announced that its subsidiary, Beijing Sai Er Biological Pharmaceutical Co., Ltd., has received a renewed Drug Production License from the Beijing Drug Administration, valid until October 19, 2030 [1] Group 1 - The renewed Drug Production License signifies compliance with regulatory standards, enhancing the company's operational capabilities in the pharmaceutical sector [1] - The license renewal is a critical step for the company to continue its production activities and potentially expand its market presence [1]